Ignace Vergote
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer
Van Asten K, Van Calster B, Christodoulou E, Vergote I, Thürlimann B, Viale G, Regan M, Giobbie-Hurder A, Paridaens R, Smeets A, Weltens C, Van Limbergen E, Floris G, Wildiers H, Brouckaert O, Jongen L, Olbrecht S, Slembrouck L, Neven P. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. Oncologist 2018
31.08.2018Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer
31.08.2018Oncologist 2018
Van Asten Kathleen, Van Calster Ben, Christodoulou Evangelia, Vergote Ignace, Thürlimann Beat, Viale Giuseppe, Regan Meredith M, Giobbie-Hurder Anita, Paridaens Robert, Smeets Ann, Weltens Caroline, Van Limbergen Erik, Floris Giuseppe, Wildiers Hans, Brouckaert Olivier, Jongen Lynn, Olbrecht Siel, Slembrouck Laurence, Neven Patrick
Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
Neven P, Vuylsteke P, Wynendaele W, Casteels M, Van Huffel S, Lybaert W, Van Ginderachter J, Paridaens R, Vergote I, Dezentjé V, Van Calster B, Jörger M, Verhoeven D, Berteloot P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D, Poppe A, Wildiers H, Dieudonné A, Brouckaert O, Decloedt J, Guchelaar H. Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial. Clin Cancer Res 2018; 24:2312-2318.
19.02.2018Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
19.02.2018Clin Cancer Res 2018; 24:2312-2318
Neven Patrick, Vuylsteke Peter, Wynendaele Wim, Casteels Minne, Van Huffel Sabine, Lybaert Willem, Van Ginderachter Johan, Paridaens Robert, Vergote Ignace, Dezentjé Vincent Olaf, Van Calster Ben, Jörger Markus, Verhoeven Didier, Berteloot Patrick, Jongen Lynn, Lintermans Anneleen, Van Asten Kathleen, Blomme Chantal, Lambrechts Diether, Poppe An, Wildiers Hans, Dieudonné Anne-Sophie, Brouckaert Olivier, Decloedt Jan, Guchelaar Henk-Jan
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial
Joly F, Huober J, Dell'Anna T, Ferrandina G, Vergote I, Reinthaller A, Vaughan M, Sugimoto A, Boman K, Donoghoe M, Fabbro M, Ray-Coquard I, Pujade-Lauraine E. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol 2011; 122:226-32.
14.05.2011Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial
14.05.2011Gynecol Oncol 2011; 122:226-32
Joly Florence, Huober Jens, Dell'Anna Tiziana, Ferrandina Gabriella, Vergote Ignace, Reinthaller Alexander, Vaughan Michelle, Sugimoto Akira, Boman Karin, Donoghoe Mark, Fabbro Michel, Ray-Coquard Isabelle, Pujade-Lauraine Eric